

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

**Daiichi Sankyo to Launch Mema[®]ry 5mg, 10mg and 20mg Tablets
for the Treatment of Alzheimer's Disease**

TOKYO, Japan (April 27, 2011) — Daiichi Sankyo Company, Limited today announced that it will launch Mema[®]ry 5mg, 10mg and 20mg Tablets (generic name: Memantine Hydrochloride, Approval to Manufacture and Market: January 21) given once daily for the treatment of moderate to severe Alzheimer's Disease on Wednesday, June 8.

The launch in Japan of Mema[®]ry had previously been postponed on March 16 following the Tohoku Pacific Offshore Earthquake.

###